The economic costs of pain in the United States.
By Darrell J. Gaskin, P. Richard. Journal of Pain, 2012
2,295 citations recorded by the source corpus.
Subfields: Anesthesiology and Pain Medicine, Pharmacology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/91e84ccbb101ba2b98d1357371640611e0d21210
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Anesthesiology and Pain Medicine
In Pharmacology
In Public Health, Environmental and Occupational Health
Citations in the corpus
- The role of psychosocial processes in the development and maintenance of chronic pain disorders (2016, positive): “In the United States, chronic pain is estimated to affect over 100 million adults at any given time, is among the leading causes of reduced quality of life, and carries direct and indirect costs of over $600 billion dollars annually in the United States alone.(72) Moreover, the experience of persist”
- Epidemiology of Low Back Pain in Adults (2014, background): “Gaskin and Richard (12) described the economic costs of pain in the USA based on the 2008 Medical Expenditure Panel Survey.”
- The individual and societal burden of chronic pain in Europe: the case for strategic prioritisation and action to improve knowledge and availability of appropriate care (2013, background): “Country (pricing year) Ireland (2008) [30] Sweden (2008) [43] Denmark (2010) [41] United States (2010) [42]”
- Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis (2015, background): “This is an intriguing issue and although there are likely many factors involved, neither the abundance of opioids prescribed for the treatment of chronic pain nor the large proportion of studies of problematic opioid use seem to have helpfully diminished the prevalence, impact, or cost of chronic pa”
- Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999–2010 (2014, background): “We also included 4 time-varying state-level factors: (1) the presence of a state-level prescription drug monitoring program (a state-level registry containing information on controlled substances prescribed in a state),16 (2) the presence of a law requiring or allowing a pharmacist to request patien”